文献速递血液净化与透析水电解质与酸碱

Tenapanor对血液透析患者磷结合剂片剂负担的影响

Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients.
PubMed 文献 · Kidney Int Rep · 2021-07-08

这项多中心、开放标签、单臂研究纳入67例日本血液透析患者,在磷结合剂方案上加用Tenapanor 30mg每日两次,调整磷结合剂剂量使血磷维持在基线±0.5mg/dl范围内。主要终点为每日磷结合剂与Tenapanor片剂总数较基线下降≥30%的患者比例,结果71.6%达到主要终点(P<0.001),平均片剂数从14.7片/日降至3.0片/日,血磷控制良好,但腹泻发生率达74.6%。

要点

  • Tenapanor可显著减少血液透析患者磷结合剂片剂负担
  • 71.6%患者每日总片剂数较基线下降≥30%
  • 腹泻是最常见药物相关不良事件,发生率为74.6%

核心结论

  • Tenapanor有效控制血磷并减少磷结合剂片剂数量。
  • 药物相关腹泻的管理将促进Tenapanor更广泛使用。

研究设计与样本

  • 多中心、开放标签、单臂研究,纳入67例日本血液透析患者,其中43例完成研究。
  • 患者血清磷水平为3.5至7.0 mg/dl,在磷结合剂方案基础上加用Tenapanor 30mg每日两次口服。
  • 磷结合剂剂量调整以使血清磷水平维持在基线±0.5 mg/dl范围内,治疗期26周。

主要发现

  • 基线时每日磷结合剂片剂平均总数为14.7片,第26周降至3.0片/日。
  • 主要终点(每日磷结合剂与Tenapanor片剂总数较基线下降≥30%)在71.6%患者中达成(P<0.001)。
  • 28.4%患者磷结合剂完全转换为Tenapanor(P<0.001)。
  • 平均血磷水平基线为5.19 mg/dl,第26周为4.71 mg/dl,控制相对良好。
  • 最常见的药物相关不良事件为腹泻(74.6%)。

临床怎么用

  • 对于血液透析高磷血症患者,可考虑加用Tenapanor以减少磷结合剂片剂负担并维持血磷控制。
  • 需关注并管理Tenapanor相关腹泻以保障治疗持续性。

局限性

  • 单臂设计,无对照,样本量有限(67例入组,43例完成)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The current management of hyperphosphatemia with phosphate binders is associated with insufficient phosphorus control and a significant pill burden. Tenapanor, a first-in-class, phosphate absorption inhibitor, is expected to control phosphorus and decrease pill burden because of its small pill size and twice daily dosing regimen. This study evaluated tenapanor effectiveness on reducing the phosphate binder pill burden during a 26-week treatment period in Japanese hemodialysis patients. METHODS: In this multicenter, open-label, single-arm study, hemodialysis patients whose serum phosphorus level was 3.5 to 7.0 mg/dl received tenapanor 30 mg twice daily orally added to their phosphate binder regimen. The phosphate binder dosage was adjusted to achieve a serum phosphorus level within the baseline range of ±0.5 mg/dl. The primary end point was the percentage of patients who achieved a ≥30% decrease in the number of phosphate binders and tenapanor tablets prescribed daily compared with the number of phosphate binder tablets at baseline. RESULTS: Of the 67 patients enrolled, 43 completed the study. At baseline, the mean total number of phosphate binder tablets per day was 14.7, which decreased to 3.0 tablets per day at week 26. The primary end point was achieved in 71.6% of patients (P < 0.001). The phosphate binder was completely switched to tenapanor in 28.4% of patients (P < 0.001). The mean phosphorus levels were relatively well controlled (5.19 and 4.71 mg/dl at baseline and week 26, respectively). The most frequent drug-related adverse event (AE) was diarrhea (74.6%). CONCLUSION: Tenapanor provided effective phosphorus control and decreased the number of phosphate binder tablets. The management of drug-related diarrhea will facilitate more widespread use of tenapanor.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Akizawa T, Sato Y, Ikejiri K, et al. Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients. Kidney Int Rep. 2021. PMID: 34514198. doi:10.1016/j.ekir.2021.06.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。